new version V2017

melanoma
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

B-Raf enzyme inhibitors

vemurafenib
BRIM 8 (cohort IIIC)vemurafenibplaceboNegative
BRIM 8, 2018vemurafenibplaceboadjuvantSuggestingNCT01667419

combined BRAF-MEK inhibitors

encorafenib plus binimetinib
COLUMBUS, 2018encorafenib plus binimetinibvemurafenib1LSuggestingNCT01909453
selumetinib
Kirkwood, 2012selumetinibtemozolomide -
trametinib + dabrafenib
Flaherty, 2012trametinib and dabrafenibdabrafenibSuggestingNCT01072175
COMBI-D (Long), 2014trametinib and dabrafenibdabrafenib1L unresectableSuggestingNCT01584648
COMBI-V (Robert), 2015trametinib and dabrafenibvemurafenib1LSuggestingNCT01597908
COMBI-AD, 2017trametinib and dabrafenibplaceboadjuvantSuggestingNCT01682083
vemurafenib and cobimetinib
Larkin, 2014vemurafenib and cobimetinibvemurafenibSuggestingNCT01689519
GO28141 ongoing cobimetinib + vemurafenibvemurafenib alone - NCT01689519

immune checkpoint inhibition

ipilimumab
Hodi (ipi alone), 2010ipilimumab 3 mg/kggp1002L Risk of bias SuggestingNCT00094653
Hodi (ipi + gp100), 2010ipi + gp100gp1002L Risk of bias SuggestingNCT00094653
Robert, 2011ipilimumab + dacarbazinedacarbazine1L Low risk of bias ConclusiveNCT00324155
EORTC 18071 (Eggermont), 2015ipilimumabplaceboadjuvant Low risk of bias Conclusive NCT00636168
nivolumab
CheckMate 037 (Weber), 2015nivolumabchemotherapy2L, anti-CTLA-4 failure Risk of bias SuggestingNCT01721746
CheckMate 066 (Robert), 2015nivolumabdacarbazine1L Low risk of bias Conclusive NCT01721772
CheckMate 067 (nivo + ipi vs ipi), 2015nivolumab + ipilimumabipilimumab1L Low risk of bias Conclusive NCT01844505
Postow, 2015nivolumab + ipilimumabipilimumab1L Exploratory - NCT01927419
CheckMate 067 (nivo vs ipi), 2015nivolumabipilimumab1L Low risk of bias ConclusiveNCT01844505
CheckMate 067 (nivo + ipi vs nivo), 2015nivolumab + ipilimumabnivolumab1L Exploratory - NCT01844505
CheckMate 238, 2017nivolumabipilimumabadjuvant Low risk of bias ConclusiveNCT02388906
pembrolizumab
KEYNOTE-001, 2014pembrolizumab 2mg/kgpembrolizumab 10mg/kg2L Exploratory NegativeNCT01295827
KEYNOTE 002 (2mg/kg Q3W), 2015pembrolizumab 2mg/kgchemotherapy2L Exploratory Suggesting NCT01704287
KEYNOTE 002 (10mg/kg Q3W), 2015pembrolizumab 10mg/kgchemotherapy2L Exploratory SuggestingNCT01704287
KEYNOTE-006 (every 2W), 2015pembrolizumab (every 2W)ipilimumab1L Risk of bias Suggesting NCT01866319
KEYNOTE-006 (every 3W), 2015pembrolizumab (every 3W)ipilimumab1L Risk of bias Suggesting NCT01866319
KEYNOTE-054, 2018pembrolizumabplaceboadjuvant Low risk of bias Conclusive NCT02362594

interferon BIS A EFFACER

Interferon alpha
EORTC18871/DKG 80-1 stage IIIrIFN alpha-2bobservation -
EORTC18871/DKG 80-1 (Kleeberg), 2004rIFN alpha-2bobservationadjuvantNegative
EORTC18952 (Eggermont), 2005ID IFN alpha-2b (I M)observationadjuvantNegative
EORTC18991 (Eggermont), 2008PEG IFN alpha-2b (I M)observationadjuvantSuggesting
Nordic IFN Trial, 2011ID IFN alpha-2b (I M)observationadjuvantSuggesting

MEK inhibitor

selumetinib
Kirkwoodselumetinibtemozolomide -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons